The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://haimadsys778862.wikinstructions.com/28574/glp_3_retatrutide_a_comparative_analysis